2026-05-21T23:05:50Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/112872025-05-07T10:04:47Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19611col_20.500.12105_16967col_20.500.12105_16988

00925njm 22002777a 4500 dc Herrador, Zaida author Pérez-Molina, José A author Henríquez Camacho, César Augusto author Rodríguez-Guardado, Azucena author Bosch-Nicolau, Pau author Calabuig, Eva author Domínguez-Castellano, Angel author Pérez-Jacoiste, María Asunción author Ladrón de Guevara, M Concepción author Mena, Ana author Ruiz-Giardin, José Manuel author Torrús, Diego author Wikman-Jorgensen, Philip author Benito, Agustin author López-Vélez, Rogelio author 2020 Background: Neurocysticercosis (NCC) is the most common parasitic neurological disease worldwide and a major cause of epilepsy. Spain is the country reporting the highest number of NCC imported cases in Europe. Methodology: Retrospective case series of NCC patients registered in the +REDIVI Network from October 1, 2009 to July 2018. A specific questionnaire, including clinical and diagnostic characteristics, was created and sent to the collaborator centers. Results: 46 cases were included in the analysis. 55% were male, mean age of 40 years. 95.6% were migrants. The median duration since migration from an endemic area was 10 years. Predominant nationalities were Ecuadorians (50%) and Bolivians (30.4%). Frequent locations were parenchymal (87%), subarachnoid (26.1%) and intraventricular cysts (10.9%). Serological analysis was performed in 91.3%, being 54.8% positive. Most prevalent clinical manifestations were persistent headache (60.9%), epilepsy (43.5%) and visual changes (13%). Patients were mainly treated with albendazole (76.1%), corticosteroids (67.4%), and anticonvulsionants (52.2%). 82.5% had a favorable clinical outcome. Conclusions: Most NCC cases were long-standing migrants. Few clinical differences were observed depending on the cysticerci location. The treatment was often not according to current recommendations, and no uniform criteria were followed when it came to the therapeutic regimen. NCC case management in Spain (including clinician awareness and laboratory capacity improvements) needs to be strengthened. Travel Med Infect Dis. Sep-Oct 2020;37:101683. 10.1016/j.tmaid.2020.101683 1873-0442 1477-8939 Travel medicine and infectious disease http://hdl.handle.net/20.500.13003/17336 32335208 L2005760765 2-s2.0-85084208273 http://hdl.handle.net/20.500.12105/11287 580476900018 Imported cysticercosis in Spain: A retrospective case series from the +REDIVI Collaborative Network